Philip Daffas
Directeur Général chez PAINCHEK LIMITED
Fortune : 488 248 $ au 31/05/2024
Profil
Philip Daffas is currently the CEO, Non-Executive Director & Managing Director at PainChek Ltd.
He previously held positions as the Chief Executive Officer at Applied Physiology Pty Ltd., Global Marketing Director at Roche Diagnostics GmbH, Managing Director at Bio-Rad Laboratories Pty Ltd., Vice President-Global Marketing at Cochlear Ltd., Head-Sales & Marketing at IVAC Corp., Principal at Shiley Infusaid, Inc., and General Manager at Roche Diagnostics Australia Pty Ltd.
Mr. Daffas has an MBA from Kingston University and an undergraduate degree from the University of Westminster.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PAINCHEK LTD
1,55% | 11/03/2024 | 25 310 946 ( 1,55% ) | 488 248 $ | 31/05/2024 |
Postes actifs de Philip Daffas
| Sociétés | Poste | Début |
|---|---|---|
| PAINCHEK LIMITED | Directeur Général | 03/04/2017 |
Anciens postes connus de Philip Daffas
| Sociétés | Poste | Fin |
|---|---|---|
| COCHLEAR LIMITED | Sales & Marketing | 01/01/2002 |
| Bio-Rad Laboratories Pty Ltd. | Corporate Officer/Principal | - |
| Roche Diagnostics Australia Pty Ltd. | Corporate Officer/Principal | - |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Sales & Marketing | - |
| Shiley Infusaid, Inc. | Corporate Officer/Principal | - |
Formation de Philip Daffas
| Kingston University | Masters Business Admin |
| University of Westminster | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| COCHLEAR LIMITED | Health Technology |
| PAINCHEK LIMITED | Technology Services |
| Entreprise privées | 6 |
|---|---|
IVAC Corp.
 IVAC Corp. Medical SpecialtiesHealth Technology Part of River Acquisition Corp., IVAC Corp. is a company that manufactures electronic medical equipment. The company is based in San Diego, CA. IVAC was acquired by River Acquisition Corp. from Eli Lilly & Co. on November 29, 1994. | Health Technology |
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Commercial Services |
Applied Physiology Pty Ltd.
 Applied Physiology Pty Ltd. Medical DistributorsDistribution Services Applied Physiology developed and commercializes guidance devices for use in the critical care environment. Navigator™, the flagship product, focuses on hemodynamic management. Applied Physiology aims to develop products that make life easier for the clinician. The devices continuously acquire physiological data from conventional monitors and use it to create a graphical depiction of the patient position, and continuous advice on the next therapy. Applied Physiology's devices enable the implementation of targeted therapy to optimize care and outcomes. The clinician specifies target ranges for the variables being monitored. The devices graphically display the patient position in relation to these targets, and indicate a course of therapy that will guide the patient to the target area. This self-adaptive protocol facilitates a safe and systematic approach to bedside care, where whole teams work toward a unified goal. Applied Physiology's therapeutic guidance devices have demonstrated potential benefits for both clinicians and patients: Clinical teamwork is enhanced and goals unified, Improved patient put comes, Reduced length of stay and Reduced morbidity in critical care units. At the heart of Applied Physiology's technology are mathematical algorithms based on a combination of systems physiology and control engineering methods. This rigorous basis has enabled the development of sound and reliable patient-specific solutions to treatment planning problems that are often counter-intuitive. Applied Physiology's flagship product Navigator™, which targets pressure and flow in the circulatory system, will be available for sale in Europe and Australia in the second quarter 2010. It will be available for sale in the U.S. pending regulatory approval from the FDA. The company is based Australia, and established European operations in the UK in 2008. | Distribution Services |
| Shiley Infusaid, Inc. | |
| Bio-Rad Laboratories Pty Ltd. | |
| Roche Diagnostics Australia Pty Ltd. |
